Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $10.0 million.

  • Arcutis Biotherapeutics' Share-based Compensation rose 258.59% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year decrease of 339.95%. This contributed to the annual value of $41.7 million for FY2024, which is 751.55% up from last year.
  • Arcutis Biotherapeutics' Share-based Compensation amounted to $10.0 million in Q3 2025, which was up 258.59% from $10.5 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Share-based Compensation high stood at $12.5 million for Q2 2024, and its period low was $4.3 million during Q2 2021.
  • Over the past 5 years, Arcutis Biotherapeutics' median Share-based Compensation value was $9.4 million (recorded in 2024), while the average stood at $8.8 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Share-based Compensation surged by 75888.89% in 2021 and then plummeted by 2316.83% in 2022.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Share-based Compensation stood at $5.7 million in 2021, then soared by 62.93% to $9.3 million in 2022, then dropped by 5.47% to $8.8 million in 2023, then rose by 7.26% to $9.4 million in 2024, then grew by 6.86% to $10.0 million in 2025.
  • Its Share-based Compensation was $10.0 million in Q3 2025, compared to $10.5 million in Q2 2025 and $9.8 million in Q1 2025.